New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib

Tumori. 2012 Jul-Aug;98(4):e102-4. doi: 10.1177/030089161209800422.

Abstract

Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of EGFR mutations confirmed he had a sensitive mutation (exon 19 deletion). This case supports that icotinib has great efficacy in advanced non-small cell lung cancer with sensitive EGFR mutations.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / surgery
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Crown Ethers / administration & dosage
  • Crown Ethers / therapeutic use*
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use*
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism*
  • Exons
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / surgery
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / surgery
  • Neoplasm Staging
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Quinazolines / administration & dosage
  • Quinazolines / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Crown Ethers
  • Enzyme Inhibitors
  • Quinazolines
  • icotinib
  • ErbB Receptors
  • Protein-Tyrosine Kinases